United States Drug Patent 4,598,089: Claim Scope, Orlistat Coverage, Expiration, and Patent Landscape

U.S. Patent No. 4,598,089 covers lipstatin, tetrahydrolipstatin, pharmaceutical compositions containing either compound, and therapeutic use for obesity and hyperlipidemia through pancreatic-lipase inhibition. The saturated compound in claims 3, 8, 11, 15, 19 and related claims is tetrahydrolipstatin, now known as orlistat. The patent issued July 1, 1986, and its 17-year pre-1995 patent term expired July 1, 2003. It no longer blocks generic orlistat development or commercial entry.

What compounds does U.S. Patent 4,598,089 protect?

The patent claims two closely related beta-lactone compounds:

Compound	Structural characteristic	Modern identification
Compound with `A` as an unsaturated chain	Contains 7Z and 10Z double bonds	Lipstatin
Compound with `A` as `-(CH2)5-`	Fully hydrogenated side chain	Tetrahydrolipstatin, orlistat

The principal covered structure is a beta-lactone bearing:

A hexyl substituent;
A 3-hydroxy group;
A stereochemically defined 5-substituted side chain;
An ester of (S)-2-formamido-4-methylvaleric acid;
Either a diene-containing side chain or a fully saturated side chain.

The saturated species is the commercially important compound orlistat. Its commonly used chemical description is tetrahydrolipstatin. The drug is a gastrointestinal lipase inhibitor that reduces hydrolysis and absorption of dietary triglycerides.

The patent’s structural definition is unusually narrow at the genus level. Claim 1 does not cover an unlimited class of lipase inhibitors. It covers a compound formula in which the variable A has only two expressly identified alternatives. The practical chemical scope is therefore limited to lipstatin and tetrahydrolipstatin, subject to the exact drawing and stereochemical limitations in the issued patent. (U.S. Patent No. 4,598,089, 1986).

How do claims 1 through 3 define the compound scope?

Claim 1: two-member structural genus

Claim 1 is the broadest compound claim. It covers a formula with A defined as either:

The unsaturated structural group shown in the patent; or
A pentamethylene group, -(CH2)5-.

The claim is broad relative to claims 2 and 3 because it uses a structural formula rather than naming one stereochemically complete compound. It is still constrained by:

The beta-lactone ring;
The substitution pattern;
The formamido-methylvaleryl ester;
The stereochemistry shown in the formula;
The two permitted versions of A.

A compound that retains the same core structure but changes the stereochemistry, replaces the formamido group, modifies the hexyl substituent, or changes the lactone ring would not fall within the literal scope of claim 1 unless the patent’s formula and accepted claim-construction principles still encompass that modification.

Claim 2: lipstatin

Claim 2 identifies the unsaturated compound as:

(2S,3S,5S,7Z,10Z)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-7,10-hexadecadienoic 1,3 acid lactone.

This is lipstatin. The claim requires the specified absolute stereochemistry and the two cis-configured double bonds at the 7Z and 10Z positions. A saturated analog is outside claim 2 but may fall within claim 3.

Claim 3: tetrahydrolipstatin and orlistat

Claim 3 identifies the saturated compound:

(2S,3S,5S)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-hexadecanoic 1,3 acid lactone.

This is tetrahydrolipstatin, the active ingredient later commercialized as orlistat in Xenical and alli products. Claim 3 is a direct product claim to the active pharmaceutical ingredient, not merely a claim to its use or a formulation.

That distinction was commercially important during the patent term. A product containing chemically identical orlistat would have implicated the compound claim regardless of whether the manufacturer used a different manufacturing process, supplier, excipient system, or dosage form.

What pharmaceutical compositions are protected?

Claims 4 through 8 cover compositions containing either lipstatin or tetrahydrolipstatin.

Claim	Subject matter
4	Composition containing about 5% to 95% active compound and 5% to 95% inert carrier, delivering about 0.1 to 100 mg/kg/day
5	Oral unit dosage form
6	Tablet, dragee, capsule, solution, emulsion, or suspension
7	Composition containing lipstatin
8	Composition containing tetrahydrolipstatin

Composition concentration range

Claim 4 requires both:

About 5% to about 95% of the active compound; and
About 5% to 95% of a pharmaceutically acceptable inert carrier.

The percentages are composition-level limitations. A formulation outside those stated ranges may avoid literal infringement of claim 4, although the compound itself could have been covered independently by claims 1 through 3 during the patent term.

The claim also requires a dosage amount sufficient to supply approximately 0.1 to 100 mg/kg/day. This is a broad dose range. It covers a large range of experimental and clinical dosing, but the dose limitation does not expand the underlying compound scope.

Oral dosage forms

Claims 5 and 6 narrow claim 4 to oral administration and then list specific dosage forms. The listed forms include conventional oral pharmaceutical products:

Tablets;
Dragees;
Capsules;
Solutions;
Emulsions;
Suspensions.

The claims do not expressly require a particular delayed-release coating, enteric system, particle size, excipient, dissolution profile, or capsule technology. As a result, the formulation claims are much less technically specific than later formulation patents commonly used for commercial products.

What methods of treatment are protected?

Claims 9 through 20 are method-of-treatment claims directed to obesity, hyperlipidemia, and prevention of obesity.

Claims	Therapeutic indication	Active compound	Dose limitation
9-12	Treatment of obesity	Lipstatin or tetrahydrolipstatin	0.1 to 100 mg/kg/day in claim 12
13-16	Treatment of hyperlipidemia	Lipstatin or tetrahydrolipstatin	0.1 to 100 mg/kg/day in claim 16
17-20	Prevention of obesity by inhibiting pancreatic lipase	Lipstatin or tetrahydrolipstatin	0.1 to 100 mg/kg/day in claim 20

Obesity treatment claims

Claim 9 requires administration of the claimed compound to an afflicted mammal in an amount effective to treat obesity. Claims 10 and 11 identify lipstatin and tetrahydrolipstatin separately. Claim 12 adds the stated daily dose range.

The claim language is functional. It does not require a specific amount below or above the dependent-claim range unless the asserted claim includes that limitation. It also does not require a specific reduction in body weight, body-mass index, fat absorption, or fecal fat excretion.

Hyperlipidemia claims

Claims 13 through 16 extend the therapeutic coverage to hyperlipidemia. The claims do not identify a particular lipid endpoint, such as LDL cholesterol, triglycerides, total cholesterol, or postprandial lipemia.

A product using orlistat for weight management could have implicated both the obesity and hyperlipidemia claims if the treatment facts satisfied the relevant limitations. Because the patent expired in 2003, these method claims have no current exclusionary effect.

Obesity-prevention claims

Claims 17 through 20 cover prevention of obesity through pancreatic-lipase inhibition. This is a broader prophylactic concept than treatment of an existing obesity condition. The claim requires administration of the compound in an amount effective to prevent obesity by inhibiting pancreatic lipase.

The typographical wording in the supplied claim, "pancrease lipase," should be read in context as pancreatic lipase. The patent’s technical disclosure and the pharmacology of lipstatin and tetrahydrolipstatin support that interpretation.

When did U.S. Patent 4,598,089 expire?

U.S. Patent No. 4,598,089 issued July 1, 1986. Because it was an older U.S. application governed by the pre-1995 patent-term rule, its basic term was 17 years from grant. The resulting expiration date was July 1, 2003. (U.S. Patent No. 4,598,089, 1986; U.S. Patent and Trademark Office, n.d.).

Event	Date
Patent issued	July 1, 1986
Basic term	17 years from issue
Patent expiration	July 1, 2003
Current status	Expired
Current Paragraph IV risk	None for this patent
Current Orange Book blocking effect	None

The expiration ended enforceable rights in the compound, composition, and method claims. A manufacturer entering after expiration does not need a license from the original patent owner to practice the expired claims.

What was the FDA regulatory status of orlistat?

The FDA approved Xenical, containing 120 mg of orlistat, for chronic weight management in conjunction with a reduced-calorie diet. The approved labeling describes orlistat as an inhibitor of gastrointestinal lipases. The drug acts locally in the gastrointestinal tract and reduces absorption of dietary fat. (U.S. Food and Drug Administration, 1999).

The FDA later approved alli, a lower-dose 60 mg orlistat product, for nonprescription use in adults. The regulatory distinction between prescription Xenical and OTC alli did not change the expiration of U.S. Patent 4,598,089.

Product	Active ingredient	Strength	Regulatory category
Xenical	Orlistat	120 mg	Prescription
alli	Orlistat	60 mg	Over-the-counter

Orlistat is a small-molecule drug. It is not a biologic, and biosimilar regulations do not apply. Competitive products therefore enter through conventional abbreviated or full small-molecule drug pathways rather than the biosimilar pathway under section 351(k) of the Public Health Service Act.

What was the Orange Book status of U.S. Patent 4,598,089?

U.S. Patent 4,598,089 could have supported historical Orange Book patent listing for an orlistat product, subject to the sponsor’s listing decisions and the FDA’s applicable requirements. It is no longer an unexpired patent that can delay approval or launch of an orlistat product.

The relevant legal consequences are:

An expired compound patent cannot support a new 30-month stay.
A current ANDA applicant does not need to certify that it will wait for expiration of this patent.
A Paragraph IV certification directed solely to this expired patent would not create a present patent-exclusion period.
The patent does not provide current market exclusivity for Xenical, alli, or generic orlistat.

FDA approval of a generic product can still depend on other listed patents, exclusivities, labeling requirements, manufacturing controls, or regulatory deficiencies. Those issues are separate from the expired rights in U.S. Patent 4,598,089.

Which companies challenged the patent, and what is the litigation status?

There is no current litigation risk associated with U.S. Patent 4,598,089 because the patent expired in 2003. Any historical Paragraph IV dispute concerning this patent would be moot as a source of future exclusionary rights.

The original patent owner and commercial developer associated with lipstatin and orlistat was F. Hoffmann-La Roche Ltd. Roche commercialized Xenical. GlaxoSmithKline later marketed alli in the United States under a commercial arrangement involving the orlistat product.

The patent itself does not contain process claims. This limits the litigation theories that could have been asserted against an API manufacturer. During its term, the principal theories would have involved:

Making or selling the claimed compound;
Selling a composition containing the compound;
Inducing use for obesity or hyperlipidemia;
Direct or induced infringement tied to labeled therapeutic use.

After expiration, these theories no longer provide a viable basis for prospective patent enforcement under this patent.

How strong was the patent estate?

Strengths during the patent term

The patent had several strong claim characteristics:

Claims 2 and 3 were direct claims to specifically identified compounds.
Claim 3 covered tetrahydrolipstatin, the later commercial active ingredient orlistat.
The claims included stereochemical detail.
A compound claim could reach the API regardless of manufacturing route.
Treatment claims covered the core commercial indications.

The direct product claim was the most commercially important provision. A generic manufacturer could not avoid it by changing excipients or dosage form.

Limitations during the patent term

The estate also had material limitations:

The patent did not claim a manufacturing process.
The formulation claims used broad percentage and dosage limitations.
No specific controlled-release, enteric, particle-size, polymorph, or stability technology appears in the supplied claims.
The method claims required proof of the claimed therapeutic use.
The patent had a relatively short remaining life by the time Xenical reached the U.S. market in 1999.

The original patent therefore had strong API coverage but a comparatively narrow secondary patent platform based on the supplied claims.

What generic entry risks exist for orlistat?

The core API risk is no longer present because the patent expired. Generic entry analysis should instead focus on:

Any later formulation patents;
Product-specific Orange Book listings;
Labeling differences between prescription and OTC products;
Manufacturing specifications;
Impurity and degradation controls;
Bioequivalence;
Drug-product quality and dissolution;
Any applicable pediatric, clinical, or regulatory exclusivity.

The patent does not create a biosimilar risk because orlistat is a small molecule. The primary post-expiration competitive threat is conventional generic substitution.

How does this patent compare with later orlistat protection?

U.S. Patent 4,598,089 is best characterized as a foundational composition-and-use patent. Later protection, where available, would have had to focus on narrower technical subject matter, such as:

Improved pharmaceutical formulations;
Manufacturing processes for tetrahydrolipstatin;
Purification and impurity control;
Solid-state or stability properties;
Specific dosage regimens;
Combination therapy;
Packaging or product presentation.

Those later patents could have created narrower and later-expiring barriers, but they could not extend the expired term of the original compound claims. A later formulation patent also would not prevent manufacture of the unclaimed API or a noninfringing formulation.

What licensing and commercial exposure were associated with the patent?

The commercial value of the patent centered on Roche’s development and commercialization of orlistat as Xenical. The patent protected the molecule before and during the early commercial period. Later alli commercialization expanded access through a lower-dose OTC product.

No current licensing payment is required to practice the expired claims. Historical commercial arrangements involving Xenical or alli do not revive U.S. Patent 4,598,089 or create current patent exclusivity.

Key Takeaways

U.S. Patent 4,598,089 covers lipstatin and tetrahydrolipstatin, including orlistat.
Claim 3 is the key API claim for tetrahydrolipstatin.
Claims 4 through 8 cover compositions and oral dosage forms.
Claims 9 through 20 cover obesity treatment, hyperlipidemia treatment, and obesity prevention through pancreatic-lipase inhibition.
The patent issued July 1, 1986, and expired July 1, 2003.
The patent is not a current barrier to generic orlistat.
Orlistat is a small molecule, so biosimilar rules do not apply.
Current entry risk depends on later formulation, manufacturing, regulatory, and product-specific patent rights, not this expired patent.
The strongest historical protection was the direct compound claim to tetrahydrolipstatin.
The estate had no process claims in the claim set supplied.

FAQs

Is tetrahydrolipstatin the same drug as orlistat?

Yes. Tetrahydrolipstatin is the compound commonly known as orlistat, the active ingredient in Xenical and alli.

Does U.S. Patent 4,598,089 cover lipase inhibitors generally?

No. Its compound claims are limited to lipstatin, tetrahydrolipstatin, and the structural alternatives defined in the patent formula. It does not cover the full class of pancreatic-lipase inhibitors.

Can a manufacturer sell generic orlistat without a license under this patent?

Yes. U.S. Patent 4,598,089 expired July 1, 2003, so it no longer requires a license or imposes a launch delay.

Does the patent cover orlistat manufacturing methods?

No process claim appears in the supplied claims. The patent covers compounds, compositions, and therapeutic methods, not a defined synthesis or purification process.

Could a later formulation patent still affect generic orlistat?

Yes. A later unexpired patent could cover a specific formulation, dosage regimen, manufacturing process, solid form, or product configuration. Such a patent would be separate from U.S. Patent 4,598,089.

References

U.S. Patent No. 4,598,089. (1986). Lipstatin, a process for its preparation and pharmaceutical compositions containing it. U.S. Patent and Trademark Office.
U.S. Food and Drug Administration. (1999). Xenical (orlistat) prescribing information. FDA.
U.S. Food and Drug Administration. (2007). alli (orlistat) over-the-counter labeling. FDA.
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Patent and Trademark Office. (n.d.). Patent term guidance for patents issued under the pre-1995 patent term regime. USPTO.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Switzerland	3415/83	Jun 22, 1983

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0129748	⤷ Start Trial	SPC/GB98/044	United Kingdom	⤷ Start Trial
European Patent Office	0129748	⤷ Start Trial	98C0042	Belgium	⤷ Start Trial
Austria	30025	⤷ Start Trial
Australia	2947884	⤷ Start Trial
Australia	572851	⤷ Start Trial
Bulgaria	60766	⤷ Start Trial
Canada	1247547	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,598,089

Summary for Patent: 4,598,089